CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Insmed Incorporated

INSM
$26.00BLarge Cap

Next catalyst

PDUFAJan 28, 2027in 73 days

Arikayce™

Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen

Get an email about INSM's next catalysts

Track Insmed (INSM) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 1 more upcoming event in our data (Phase 3 readout).See the timeline

Catalyst Timeline

2 upcoming, 1 past

Phase 3

Treprostinil Palmitil Phase 3 Est. Readout

December 2026~Treprostinil Palmitil91

Primary completion for Treprostinil Palmitil trial (NCT05649748) in Pulmonary Arterial Hypertension

Source
PDUFANext

FDA PDUFA Date ARIKAYCE (priority)

Jan 28, 2027Arikayce™

For Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen. sNDA filing. Extracted from SEC filing: EXHIBIT 99.1

Source

Upcoming FDA decisions

How INSM's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical Preparations🇺🇸North AmericaBRIDGEWATER1.3K employees
Drug Pipeline

Frequently asked questions

What is in Insmed Incorporated's drug pipeline?→

CatalystAlert tracks 19 drug candidates in Insmed Incorporated's (INSM) pipeline across Phase 3, Phase 2. Its lead program is Arikayce™ (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Insmed Incorporated's next FDA catalyst?→

Insmed Incorporated's (INSM) next tracked catalyst is a PDUFA date expected Jan 28, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track INSM biotech catalysts?→

Add INSM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Insmed Incorporated's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply